"We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and we have had some experience using the code now that it is active and been able to observe some of the initial payment processing by the payer," write Jonathan Rubenstein, MD, and Mark Painter.
"Full discussion of the various fertility preservation options and an understanding of the fertility implications of the various treatment modalities must be understood by patients for them to make optimal decisions for their reproductive futures," write the authors.
In this interview, Mark D. Tyson, MD, MPH, discusses TAR-200 and other novel investigational treatments for non–muscle-invasive bladder cancer.
"The data from the QUILT 3.032 Quality of Life study suggest that many patients not only have a durable response but also report no decline in physical function, which is very important for these patients,” says Karim Chamie, MD.
"I predict 2024 will be a banner year for progress in the management of [NMIBC], and not only will we be moving the needle but also turning up the volume in this historically quiet space," writes Michael S. Cookson, MD, MMHC, FACS.
Results from the phase 2 PemCab trial showed that the first-line combination elicited promising antitumor activity with tolerable toxicity in patients with advanced urothelial carcinoma, including those who were cisplatin ineligible.
Beyond being highly predictive of future recurrence, uMRD was also shown to enable quantitative evaluation of molecular response to nadofaragene.
Compared with placebo, darolutamide was associated with a numerically lower rate of hospitalizations when combined with androgen-deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer.
"Creating a year-to-year plan can ensure you are staying on track to accomplish your short-term and long-term goals," writes Jeff Witz, CFP.
